Reimbursement of Sativex® (Delta 9 Tetrahydrocannabinol (THC)/Cannabidiol (CBD)) Oromucosal Spray

The HSE has approved Sativex® oromucosal spray under High Tech Arrangements effective 1 October 2023 through a Managed Access Protocol (HSE-MAP) that will enable individual reimbursement approval for patients who meet the criteria outlined in the HSE-MAP. For more information, see HSE Circular 027/23.